Drugs affecting biliary composition and flow (Formulary)

Important: Formulation and dosage details

Formulation:

Tablets 250mg

Dosage:

Primary biliary cirrhosis: 10 to 15mg/kg daily in 2 to 4 divided doses. Tolerance can vary between individual brands; if necessary consider brand name prescribing.

Important: Formulation and dosage details

Formulation:

Capsules 250mg

Dosage:

Primary biliary cirrhosis: 10 to 15mg/kg daily in 2 to 4 divided doses. Tolerance can vary between individual brands; if necessary consider brand name prescribing.

Important: Formulation and dosage details

Formulation:

Tablets (Ocaliva^®) 5mg, 10mg (Specialist recommendation only)

Dosage:

Primary biliary cirrhosis/cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid as per SMC 2132/17.

Initiation only on discussion and advice from the Liver MDT. All patients should be reviewed at 1 year to discontinue if no biochemical response.

Note: The most commonly reported adverse reaction is pruritus, which may lead patients to discontinue treatment. Manufacturer information states that the majority occurred within the first month of treatment and tended to resolve over time with continued dosing. To be discussed with patient with a plan for treatment, if needed.